Discovering levofloxacin prototypes for anti-inflammatory and anti-bacterial activity discovering

Abstract

Sepsis is a chronic inflammatory disease involving other diseases as well. Different stages of sepsis lead to organ dysfunction and eventually death. Sepsis is recognized as an uncontrolled and dysregulated host immunological response to any infection or damage. A multitude of injuries or diseases can result in sepsis. The pathophysiology of sepsis is still unknown. Thus, a therapeutic approach for sepsis should be highly potential. Sepsis is caused by polymicrobial species such as bacteria, fungi, viruses or even parasites. The research claimed may be a therapeutic drug medication that targets major inflammatory immune responses. In sepsis, causing microorganisms are also prime important as an exaggerated immune response. In this project, we are targeting our novel drug molecules against the causes of the disease as well as immune response targets. Thus, we majorly target sepsis. Our dual drug targets, DNA Gyrase, and TIRAP will be inhibited by a novel drug molecule simultaneously. Whoever suffers from either bacterial sepsis or immunomodulatory sepsis, will be cured by one therapeutic drug only. Our therapeutic approach will try to treat sepsis more extensively. Despite the unknown pathophysiology of sepsis, Sepsis can be cured.